Navigation Links
Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
Date:5/15/2008

al School, Germany

-- Peter WF Wilson, Emory University School of Medicine, Atlanta, GA, USA

For further information on the REACH Registry please visit http://www.REACHRegistry.org

References

(1.) Grau AJ, Weimar C, Buggle F et al. Risk factors, outcome, and

treatment in subtypes of ischemic stroke: the German stroke data

bank. Stroke 2001;32:2559-2566.

(2.) Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of

subtype of acute ischemic stroke: definitions for use in a

multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke

Treatment. Stroke 1993;24:35-41.

(3.) Rother J, Alberts MJ, Touze et al. Risk factor Profile and Management

of Cerebrovascular Patients in the REACH Registry Cerebrovasc Dis

2008;25:366-374.

(4.) DL. Bhatt, PG. Steg, EM. Ohman, AT. Hirsch, Y. Ikeda, J-L. Mas, S.

Goto, C-S. Liau, A-J. Richard, J. Rother, PWF. Wilson, on behalf of

the REACH Registry Investigators. International prevalence,

recognition, and treatment of cardiovascular risk factors in

outpatients with atherothrombosis. JAMA 2006;295:180-189.

(5.) PG. Steg, DL. Bhatt, PWF. Wilson, R. D'Agostino, EM. Ohman, J.

Rother, C-S. Liau, AT. Hirsch, J-L. Mas, Y. Ikeda, MJ. Pencina, S.

Goto, on behalf of the REACH Registry Investigators. One-year

cardiovascular event rates in outpatients with atherothrombosis. JAMA

2007;297: 1197-1206.


'/>"/>
SOURCE REACH Registry
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
2. Biomatricas RNAstable(TM) Stabilizes RNA at Room Temperature
3. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
4. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
10. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... San Bruno, CA (PRWEB) April 21, 2015 ... Expert CRO, will sponsor and exhibit at the ACRP ... in Salt Lake City, Utah. The Association of Clinical ... largest annual clinical research conference solely focused on the ... through membership, training and development, and widely recognized industry ...
(Date:4/21/2015)... RESEARCH TRIANGLE PARK, N.C. , April ... UTHR ) announced today that it will release its ... Tuesday, April 28, 2015. United Therapeutics will ... at 9:00 a.m. Eastern Time.  The teleconference is accessible ... rebroadcast of the teleconference will be available for one ...
(Date:4/21/2015)... 21, 2015 Progyny, Inc., the new ... announced that it has secured additional capital from investors ... SR One and Merck Serono Ventures. The funding will ... the best fertility outcomes by aligning science, technology, clinics ... marketplace for families seeking fertility solutions and we are ...
(Date:4/21/2015)... Cleveleys (UK) (PRWEB) April 21, 2015 ... technology and its clinical applications will be ... Participants include engineers, scientists, regulators and clinicians ... The meeting is sponsored by Invibio Biomaterial ... polymer-based biomaterials, a specialist in manufacturing and ...
Breaking Biology Technology:PRC Clinical Sponsors The ACRP 2015 Global Conference And Meets Biotech Companies in the Salt Lake City Area. 2Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3
... Results -- HARBIN, China, Aug. 16 /PRNewswire-Asia-FirstCall/ -- ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... 16 /PRNewswire/ - Many companies in the cell therapy ... Hospira, Lonza and Life Technologies will join ISCT to ... greater strategic alignment within the industry and drive late ... Force (ITF), comprising these major corporations along with internationally ...
... ("CTI") (Nasdaq and MTA: CTIC) announced today that it ... has validated the expanded Pediatric Investigation Plan ("PIP") that ... of relapsed or refractory, aggressive non-Hodgkin,s lymphoma (NHL).  Following ... review and comment or approve the content of pediatric ...
Cached Biology Technology:Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 2Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 3Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 4Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 5Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 6Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 7Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 8Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 9Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 10Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 11Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 12Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 13Weikang Bio-Technology Reports Second Quarter 2010 Financial Results 14International Society for Cellular Therapy (ISCT) joins forces with Roche and Genzyme to launch Cell Therapy Industry Partnership. 2EMEA Validates Cell Therapeutics, Inc.'s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP) 2EMEA Validates Cell Therapeutics, Inc.'s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP) 3
(Date:3/24/2015)... PALM BEACH GARDENS, Fla. , March 24, ... of biometric identity management solutions, today announced that ... enabling premium clothing accessory retailer Goorin Bros ... login. The Crossmatch biometrics-based solution secures access to ... customers from the increased risk of data breaches. ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... the amazing repertoire of carbon nanotubes -- the ability ... tiny hollow carbon filaments about one ten-thousandth the diameter ... of the most versatile materials ever discovered. A hundred ... able to conduct electricity better than copper or to ...
... just a few calories from the daily diet can do ... it may help lessen the effects of aging. , Scientists ... that eating a little less food and exercising a little ... cell and organ damage in rats. , The discovery, described ...
... University of New South Wales (UNSW) researchers have announced they ... the potential to treat a diverse range of health problems, ... The research is published in the July issue of Nature ... due to age-related macular degeneration (AMD) and diabetic retinopathy are ...
Cached Biology News:Nanotubes used for first time to send signals to nerve cells 2Cutting calories slightly can reduce aging damage 2Cutting calories slightly can reduce aging damage 3'Molecular assassin' targets disease gene 2
Rat monoclonal [20d5] to NKG2A + C+ E ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Mouse): CHO transfected cells expressing the B6 allele of NKG2A. Entrez Gen...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
... Forma's stainless steel rack ... adjustable mechanism that permits ... shaking angles, and "snap-in" ... universal rack holder will ...
... dotLab System brings together two mature, ... immobilized capture surfaces. This combination produces ... for the detection of molecular binding ... labels. , Protein-specific capture molecules are ...
Biology Products: